Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clinical trial NCT05338892 · COMPLETED
Trial details
- NCT number
- NCT05338892
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-06-22
- Primary completion
- 2023-10-05
- Enrollment
- 595
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.